Click play icon ▶️ to listen (transcript follows below): As a sought-after medical imaging industry thought leader, Mike Harsh sat for a recorded interview by
. Cancer treatments are most effective, and patient outcomes are improved, when tumors are detected early. Imagion Biosystems is developing the MagSense® Systems for early
This article represents the viewpoint of management. MagSense® technology is taking a leading position amidst a broad trend in cancer medicine toward finding out more,
Imagion Biosystems has updated investors by lodging the latest version of its corporate presentation visuals with the Australian Securities Exchange. Content includes overviews of MagSense®
In this second segment of Bob Proulx’s presentation to investors at the 2016 NobleCon meeting, he answers the question of how magnetic relaxometry might be
In accord with ASX requirements, Imagion Biosystems’ quarterly financial statement Appendix 4C was lodged with the Australian Securities Exchange on 31 July, 2017, accompanied by
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance